FG category . | 30-year risk for incident CVD . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
N . | CVD . | CHD . | Stroke . | |||||||
Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | ||
Women | ||||||||||
FG <5.0 mmol/L | 3,314 | 205 | 15.3 (12.3, 18.3) | Reference | 127 | 8.4 (6.4, 10.3) | Reference | 96 | 8.5 (6.0, 11.0) | Reference |
FG 5.0–5.5 mmol/L | 3,816 | 247 | 15.6 (13.1, 18.2) | 1.05 (0.87, 1.25) | 153 | 9.1 (7.2, 10.9) | 1.05 (0.83, 1.32) | 108 | 7.9 (5.8, 9.9) | 0.98 (0.75, 1.28) |
FG 5.6–6.2 mmol/L | 2,313 | 201 | 15.9 (13.3, 18.4) | 1.40 (1.17, 1.69) | 130 | 9.7 (7.8, 11.7) | 1.47 (1.16, 1.86) | 91 | 7.6 (5.7, 9.4) | 1.36 (1.02, 1.80) |
FG 6.3–6.9 mmol/L | 528 | 54 | 18.6 (13.1, 24.1) | 1.65 (1.24, 2.20) | 31 | 11.9 (6.9, 16.9) | 1.53 (1.05, 2.24) | 26 | 8.0 (4.9, 11.1) | 1.70 (1.11, 2.60) |
FG ≥7.0 mmol/L or Rx | 1,044 | 230 | 38.6 (33.4, 43.8) | 3.56 (2.99, 4.24) | 145 | 25.5 (21.0, 29.9) | 3.62 (2.89, 4.55) | 123 | 21.2 (17.0, 25.5) | 4.07 (3.14, 5.26) |
Men | ||||||||||
FG <5.0 mmol/L | 1,484 | 180 | 23.5 (19.7, 27.3) | Reference | 136 | 18.6 (14.5, 22.6) | Reference | 58 | 8.4 (5.9, 10.9) | Reference |
FG 5.0–5.5 mmol/L | 2,956 | 337 | 21.5 (19.0, 24.1) | 0.94 (0.79, 1.11) | 244 | 16.0 (13.7, 18.3) | 0.90 (0.74, 1.10) | 112 | 7.2 (5.7, 8.8) | 0.97 (0.71, 1.32) |
FG 5.6–6.2 mmol/L | 2,570 | 358 | 23.3 (20.6, 26.0) | 1.15 (0.97, 1.36) | 266 | 16.8 (14.5, 19.0) | 1.13 (0.93, 1.37) | 118 | 8.6 (6.7, 10.5) | 1.17 (0.86, 1.60) |
FG 6.3–6.9 mmol/L | 706 | 138 | 31.0 (25.6, 36.3) | 1.61 (1.32, 1.97) | 104 | 24.1 (19.0, 29.2) | 1.61 (1.27, 2.04) | 44 | 9.6 (6.6, 12.6) | 1.59 (1.09, 2.34) |
FG ≥7.0 mmol/L or Rx | 899 | 267 | 47.7 (42.8, 52.7) | 2.45 (2.07, 2.90) | 194 | 35.5 (30.8, 40.2) | 2.35 (1.92, 2.88) | 101 | 17.6 (14.1, 21.1) | 2.87 (2.10, 3.93) |
FG category . | 30-year risk for incident CVD . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
N . | CVD . | CHD . | Stroke . | |||||||
Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | ||
Women | ||||||||||
FG <5.0 mmol/L | 3,314 | 205 | 15.3 (12.3, 18.3) | Reference | 127 | 8.4 (6.4, 10.3) | Reference | 96 | 8.5 (6.0, 11.0) | Reference |
FG 5.0–5.5 mmol/L | 3,816 | 247 | 15.6 (13.1, 18.2) | 1.05 (0.87, 1.25) | 153 | 9.1 (7.2, 10.9) | 1.05 (0.83, 1.32) | 108 | 7.9 (5.8, 9.9) | 0.98 (0.75, 1.28) |
FG 5.6–6.2 mmol/L | 2,313 | 201 | 15.9 (13.3, 18.4) | 1.40 (1.17, 1.69) | 130 | 9.7 (7.8, 11.7) | 1.47 (1.16, 1.86) | 91 | 7.6 (5.7, 9.4) | 1.36 (1.02, 1.80) |
FG 6.3–6.9 mmol/L | 528 | 54 | 18.6 (13.1, 24.1) | 1.65 (1.24, 2.20) | 31 | 11.9 (6.9, 16.9) | 1.53 (1.05, 2.24) | 26 | 8.0 (4.9, 11.1) | 1.70 (1.11, 2.60) |
FG ≥7.0 mmol/L or Rx | 1,044 | 230 | 38.6 (33.4, 43.8) | 3.56 (2.99, 4.24) | 145 | 25.5 (21.0, 29.9) | 3.62 (2.89, 4.55) | 123 | 21.2 (17.0, 25.5) | 4.07 (3.14, 5.26) |
Men | ||||||||||
FG <5.0 mmol/L | 1,484 | 180 | 23.5 (19.7, 27.3) | Reference | 136 | 18.6 (14.5, 22.6) | Reference | 58 | 8.4 (5.9, 10.9) | Reference |
FG 5.0–5.5 mmol/L | 2,956 | 337 | 21.5 (19.0, 24.1) | 0.94 (0.79, 1.11) | 244 | 16.0 (13.7, 18.3) | 0.90 (0.74, 1.10) | 112 | 7.2 (5.7, 8.8) | 0.97 (0.71, 1.32) |
FG 5.6–6.2 mmol/L | 2,570 | 358 | 23.3 (20.6, 26.0) | 1.15 (0.97, 1.36) | 266 | 16.8 (14.5, 19.0) | 1.13 (0.93, 1.37) | 118 | 8.6 (6.7, 10.5) | 1.17 (0.86, 1.60) |
FG 6.3–6.9 mmol/L | 706 | 138 | 31.0 (25.6, 36.3) | 1.61 (1.32, 1.97) | 104 | 24.1 (19.0, 29.2) | 1.61 (1.27, 2.04) | 44 | 9.6 (6.6, 12.6) | 1.59 (1.09, 2.34) |
FG ≥7.0 mmol/L or Rx | 899 | 267 | 47.7 (42.8, 52.7) | 2.45 (2.07, 2.90) | 194 | 35.5 (30.8, 40.2) | 2.35 (1.92, 2.88) | 101 | 17.6 (14.1, 21.1) | 2.87 (2.10, 3.93) |
. | 20-year risk for incident CVD . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Subsample with concurrent FG and HbA1c . | N . | CVD . | CHD . | Stroke . | ||||||
FG and HbA1c category . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | |
Women | ||||||||||
FG <5.6 mmol/L and HbA1c <5.7% (<39 mmol/mol) | 1,542 | 24 | 4.1 (2.0, 6.1) | Reference | 10 | 1.5 (0.3, 2.7) | Reference | 16 | 2.9 (1.2, 4.6) | Reference |
FG 5.6–6.9 mmol/L or HbA1c 5.7–6.4% (39–47 mmol/mol) | 1,085 | 19 | 4.2 (2.1, 6.4) | 1.13 (0.62, 2.04) | 10 | 2.0 (0.7, 3.3) | 1.42 (0.59, 3.40) | 9 | 2.2 (0.5, 3.9) | 0.80 (0.35, 1.80) |
FG ≥7.0 mmol/L, HbA1c ≥6.5% (≥48 mmol/mol), or Rx | 386 | 29 | 25.8 (13.4, 38.3) | 4.83 (2.84, 8.19) | 18 | 17.1 (6.2, 28.0) | 7.19 (3.35, 15.45) | 12 | 11.2 (4.1, 18.3) | 3.00 (1.43, 6.28) |
Men | ||||||||||
FG <5.6 mmol/L and HbA1c <5.7% (<39 mmol/mol) | 901 | 31 | 8.1 (4.6, 11.6) | Reference | 20 | 4.6 (2.4, 6.9) | Reference | 27 | 3.6 (0.8, 6.4) | Reference |
FG 5.6–6.9 mmol/L or HbA1c 5.7–6.4% (39–47 mmol/mol) | 957 | 40 | 10.7 (6.5, 15.0) | 1.21 (0.77, 1.92) | 27 | 8.1 (4.2, 12.1) | 1.27 (0.72, 2.25) | 26 | 3.6 (1.6, 5.7) | 0.91 (0.53, 1.54) |
FG ≥7.0 mmol/L, HbA1c ≥6.5% (≥48 mmol/mol), or Rx | 309 | 35 | 31.6 (20.7, 42.4) | 3.29 (2.07, 5.25) | 22 | 15.3 (9.2, 21.5) | 3.21 (1.78, 5.80) | 29 | 18.1 (8.3, 27.9) | 3.13 (1.88, 5.20) |
. | 20-year risk for incident CVD . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Subsample with concurrent FG and HbA1c . | N . | CVD . | CHD . | Stroke . | ||||||
FG and HbA1c category . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | Events . | Absolute risk, % (95% CI)† . | RR (95% CI) . | |
Women | ||||||||||
FG <5.6 mmol/L and HbA1c <5.7% (<39 mmol/mol) | 1,542 | 24 | 4.1 (2.0, 6.1) | Reference | 10 | 1.5 (0.3, 2.7) | Reference | 16 | 2.9 (1.2, 4.6) | Reference |
FG 5.6–6.9 mmol/L or HbA1c 5.7–6.4% (39–47 mmol/mol) | 1,085 | 19 | 4.2 (2.1, 6.4) | 1.13 (0.62, 2.04) | 10 | 2.0 (0.7, 3.3) | 1.42 (0.59, 3.40) | 9 | 2.2 (0.5, 3.9) | 0.80 (0.35, 1.80) |
FG ≥7.0 mmol/L, HbA1c ≥6.5% (≥48 mmol/mol), or Rx | 386 | 29 | 25.8 (13.4, 38.3) | 4.83 (2.84, 8.19) | 18 | 17.1 (6.2, 28.0) | 7.19 (3.35, 15.45) | 12 | 11.2 (4.1, 18.3) | 3.00 (1.43, 6.28) |
Men | ||||||||||
FG <5.6 mmol/L and HbA1c <5.7% (<39 mmol/mol) | 901 | 31 | 8.1 (4.6, 11.6) | Reference | 20 | 4.6 (2.4, 6.9) | Reference | 27 | 3.6 (0.8, 6.4) | Reference |
FG 5.6–6.9 mmol/L or HbA1c 5.7–6.4% (39–47 mmol/mol) | 957 | 40 | 10.7 (6.5, 15.0) | 1.21 (0.77, 1.92) | 27 | 8.1 (4.2, 12.1) | 1.27 (0.72, 2.25) | 26 | 3.6 (1.6, 5.7) | 0.91 (0.53, 1.54) |
FG ≥7.0 mmol/L, HbA1c ≥6.5% (≥48 mmol/mol), or Rx | 309 | 35 | 31.6 (20.7, 42.4) | 3.29 (2.07, 5.25) | 22 | 15.3 (9.2, 21.5) | 3.21 (1.78, 5.80) | 29 | 18.1 (8.3, 27.9) | 3.13 (1.88, 5.20) |
RR, relative risk; Rx, diabetes medication.
†Absolute risk estimates can account for competing risk of death but cannot adjust for covariates.